3 weeks ago
Biodeal Pharmaceuticals Raises ₹385 Crore From RMB Capitalworks For Expansion And R&D
Biodeal Pharmaceuticals is a company that helps make medicines.
It has been doing this for about twenty years.
The company just got a lot of money, ₹385 crore, from another company called RMB Capitalworks.
This is the first time Biodeal has taken money from outside investors.
The money will be used to grow the business and to research and invent new medicines.
RMB is part of a big bank from South Africa called FirstRand Bank.
In return, RMB will own a secret part of the company.
Biodeal's leader, Anurag Kumar, says they plan to enter new areas and make new medicine ingredients.
The company earned ₹325 crore last year and hopes to earn much more in the coming years.
They want to earn ₹1,200 crore by the year 2030.
Biodeal Pharmaceuticals announced a ₹385 crore investment from RMB Capitalworks for business expansion and research and development.
This is the first equity raise by the two-decade-old contract development and manufacturing organisation.
RMB Capitalworks, a unit of South African lender FirstRand Bank, will receive an undisclosed stake in the company.
Biodeal reported ₹325 crore revenue with a 20 per cent operating profit margin in FY26.
The company aims to reach ₹500 crore revenue in FY27 and ₹1,200 crore by FY30 with new launches and expansion.
- Who
- Biodeal Pharmaceuticals, led by Chairman and Managing Director Anurag Kumar, and RMB Capitalworks, managed by Anshuman Malur.
- What
- RMB Capitalworks invested ₹385 crore in Biodeal Pharmaceuticals for expansion and R&D, taking an undisclosed stake.
- Where
- Mumbai, India.
- When
- Monday, August 10, 2026.
- Why
- To fund expansion into new segments, research and development of new molecules, and help Biodeal reach revenue targets of ₹500 crore in FY27 and ₹1,200 crore by FY30.
Key facts
- Investment
- ₹385 crore
- Investor
- RMB Capitalworks
- Investee
- Biodeal Pharmaceuticals
- Investor parent
- FirstRand Bank (South Africa)
- Purpose
- Business expansion and R&D for new molecules
- FY26 revenue
- ₹325 crore
- FY26 operating profit margin
- 20%
- Revenue targets
- ₹500 crore (FY27); ₹1,200 crore (FY30)
Quotes
Anshuman Malur
Managing Partner of RMB Capitalworks
“RMB Capitalworks Managing Partner said healthcare is a core focus for the platform, adding that Biodeal, with its passionate founders, fits the investment thesis of a differentiated player primed for rapid growth”
freepressjournal.in
“The company plans to expand into new segments and undertake research and development activities for new molecules”
freepressjournal.in
Sources
Related news
Symbiotec Pharmalab to Raise ₹1,757 Crore Through IPO
Belrise Industries eyes expansion after ₹1,700-crore QIP, Hyva acquisition
Jitendra Singh urges private investment to boost biotech sector
Telangana Aims to Be India's Life Sciences Innovation Capital
Natco Pharma Invests Over Rs 130 Crore in eGenesis
Mom's Belief Parent Plans September IPO to Expand Care Centres
UP Teen Allegedly Gang-Raped on Moving Bus; Two Arrested
Delhi Police Handles 1,561 Grievances Through Thana Diwas Hearings
Delhi Police Expands Intelligence Preparations Ahead Of CJP Protest
Delhi Police Orders Intelligence Overhaul After Jantar Mantar Protests
Delhi L-G Sandhu Orders Faster Joint Action on Safety
